Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2002

View Archived Issues

Studies of pioglitazone in liver diseases discussed at AASLD meeting

Entecavir reportedly superior to lamivudine in HBV-infected patients

Amantadine in combination therapies for hepatitis C

Novel inhibitors of CDK and GSK-3 identified by Schering researchers

Series of histamine H3 antagonists for use in cognitive disorders reported by Abbott

Altana Pharma claims novel series of tryptase inhibitors with utility in airways disorders

New 5-HT2C agonists for erectile dysfunction and other disorders under study at Yamanouchi

IL-6 production inhibitors in early development at Ono

Novel substance P antagonists covered by Takeda patent

New alphavbeta3 antagonists in development at Dainippon

Potential use of vaccines in advanced prostate cancer

Albuferon in chronic hepatitis C

Zileuton reported to improve airways inflammation in cystic fibrosis

Symptom relief achieved with tiotropium in mild COPD

Oral factor Xa inhibitor enters phase I study for the treatment of thrombotic diseases

First approval obtained for Cialis

Endo and Durect to collaborate in the area of pain management

Bristol-Myers Squibb signs NF-kB license agreement with Ariad

CeNeS agrees to outlicense potential treatment for MS to Acorda

Neurocrine Biosciences reports positive results from phase III trial with indiplon-IR

Incyte Genomics to acquire Maxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...